Stem cell

GPCR Therapeutics Announces Publication on Improving Hematopoietic Stem Cell Mobilization Using Propranolol with GPC-100

Retrieved on: 
Thursday, October 26, 2023
Stem cell, Survival, Bone pain, Gq alpha subunit, Google Store, GPCR, Multiple myeloma, Propranolol, Therapy, Hope, Health, Hematological Cancer Research Investment and Education Act, CXCR4, Sickle cell disease, Research, Cell, ASCT, Mouse, Clinical trial, Risk, Cancer, HSC, G-CSF, G protein-coupled receptor, Transplant, Bone marrow, PLOS, Tumors of the hematopoietic and lymphoid tissues, Biology, Patient, B cell, Seoul National University, Pharmaceutical industry, Microbiology

These findings strongly support the use of this combination for peripheral blood HSC harvest in autologous stem cell transplant treatment in hematological cancers.

Key Points: 
  • These findings strongly support the use of this combination for peripheral blood HSC harvest in autologous stem cell transplant treatment in hematological cancers.
  • The paper, authored in collaboration with Seoul National University’s School of Biological Sciences and Institute of Microbiology, is entitled, “GPC-100, a novel CXCR4 antagonist, improves in vivo hematopoietic cell mobilization when combined with propranolol” (1).
  • The authors highlight that GPC-100 alone shows greater mobilization efficacy than a drug already approved for stem cell mobilization.
  • Increasingly, clinicians are using Autologous Stem Cell Transplant (ASCT) to treat patients, which has improved the anti-cancer response and survival compared to conventional chemotherapy.

Beam Therapeutics Announces Portfolio Prioritization and Strategic Restructuring Focused on Potential Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline

Retrieved on: 
Thursday, October 19, 2023
Stem cell, Science, Hematology, Biotechnology, Health, Workforce, Sickle cell disease, Research, Growth, Partnership, T-ALL, Investment, Patient, ESCAPE, Pharmaceutical industry, Vaccine, Beam

CAMBRIDGE, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced portfolio priorities and plans to streamline its business operations to support potential near-term value drivers and long-term growth. This plan includes cost reduction initiatives that align with the company’s near-term goals, and the anticipated cost savings are expected to extend its revised operating plan into 2026.

Key Points: 
  • This plan includes cost reduction initiatives that align with the company’s near-term goals, and the anticipated cost savings are expected to extend its revised operating plan into 2026.
  • “From the beginning, Beam’s strategy has been to develop base editing technology broadly across a diverse portfolio of programs and delivery modalities, and our science and pipeline continue to progress across the board.
  • “We are grateful for the dedication and innumerable contributions of our impacted colleagues.
  • The company’s hepatitis B virus program will be paused and designated for partnering given the requirement of specialized development and commercial capabilities.

Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Retrieved on: 
Wednesday, October 18, 2023
Stem cell, FDA, Amplification, Rachel Haurwitz, IND, Acute myeloid leukemia, Food, CRISPR, MD, PD-1, Doctor of Philosophy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Reindeer, University, Safety, MD Anderson Cancer Center, Patient, AML, Pharmaceutical industry, Vaccine

BERKELEY, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for CB-012, an allogeneic anti-C-type lectin-like molecule-1 (anti-CLL-1) CAR-T cell therapy. CB-012 will be evaluated in the multicenter, open-label, AMpLify Phase 1 clinical trial for patients with relapsed or refractory acute myeloid leukemia (r/r AML).

Key Points: 
  • BERKELEY, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for CB-012, an allogeneic anti-C-type lectin-like molecule-1 (anti-CLL-1) CAR-T cell therapy.
  • CB-012 will be evaluated in the multicenter, open-label, AMpLify Phase 1 clinical trial for patients with relapsed or refractory acute myeloid leukemia (r/r AML).
  • “Clearance of our IND application for CB-012 represents another significant milestone for Caribou as our third off-the-shelf CAR-T cell therapy enters the clinic,” said Rachel Haurwitz, PhD, Caribou’s president and chief executive officer.
  • “Both armoring strategies are designed to improve the antitumor activity of CB-012 that we believe are crucial for targeting this difficult to treat indication.”

Eighteenth edition of Fujio Cup Quiz won by Kasturba Medical College, India in the NCRM NICHE 2023 international stem cell meeting.

Retrieved on: 
Wednesday, October 18, 2023
Research, Hospitals, Health Technology, Stem Cells, Biotechnology, Training, University, Health, Science, Education, Cellular senescence, Regenerative medicine, PD, Cell biology, Urethral stricture, IDC, Tissue engineering, FCQ, Sri Ramachandra Institute of Higher Education and Research, Cell, GSZ, Multimedia, Tree (graph theory), Code, Tissue, German Society for Stem Cell Research, Genome, Kasturba Medical College, Disease, Buccal, University of Cologne, Duchenne muscular dystrophy, XVIII, Radboud University Medical Center, Hospital, Chondrocyte, McEwen Centre for Regenerative Medicine, Stem cell, Multiple sclerosis, NCRM, Thai-Nichi Institute of Technology, Safety, DMD, Autism spectrum, Synthetic biology, ASD, Edogawa, MS, B cell, Pharmaceutical industry, RM

This press release features multimedia.

Key Points: 
  • This press release features multimedia.
  • Winners and finalists of Fujio Cup Quiz (FCQ), the “FCQ Elites” are qualified to nominate the candidates for the Edogawa NICHE Prize.
  • The inaugural prize in 2018 was awarded to Prof. James E. Till for discovery of stem cells, jointly with Prof. Ernest McCulloch.
  • NCRM NICHE team is progressing in research on implications of microgravity, synthetic chemical concoctions, and biological response modifiers, on cellular senescence and immune modulation to develop solutions, especially for rare diseases and unmet needs.

Kyowa Kirin to Acquire Orchard Therapeutics

Retrieved on: 
Thursday, October 5, 2023
Acquisition, HSC, Therapy, Stem cell, Vision, Health, Research, Priority review, Morrison, Sanfilippo syndrome, Food and Drug Administration Amendments Act of 2007, DSM-IV codes, Kyowa Kirin, Frontotemporal dementia, EC, JST, MLD, Civil service commission, Health care, Food, European Commission, Biotechnology, Transaction, FDA, CVR, FTD, MPS, Guggenheim Partners, Kirin, Sanfilippo, TSE, ADS, MHRA, Morrison & Foerster, Science, PDUFA, Life, Patient, Communications satellite, Pharmaceutical industry, Vaccine, Security (finance), Orchard, Atidarsagene autotemcel

TOKYO and LONDON and BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a Japan-based global specialty pharmaceutical company (J-GSP) creating innovative medical solutions utilizing the latest biotechnology, and Orchard Therapeutics plc (Orchard Therapeutics, Nasdaq: ORTX), a global gene therapy leader, today announced the companies have entered into a definitive agreement under which Kyowa Kirin will acquire Orchard Therapeutics for $16.00 per American Depositary Share (ADS) in cash (approximately $387.4 million, or ¥57.3 billion), under which Orchard shareholders will hold an additional contingent value right (CVR) of $1.00 per ADS. An additional $1.00 CVR will be paid for a total of $17.00 per ADS, or approximately $477.6 million (¥70.7 billion) if the conditions are met.

Key Points: 
  • Kyowa Kirin has established a 2030 Vision to consistently create and deliver medicines with life-changing value that ultimately makes people smile, as a J-GSP.
  • “We are excited to announce that we have signed the Transaction Agreement to acquire Orchard Therapeutics, one of the leading providers of HSC gene therapy,” said Takeyoshi Yamashita, Ph.D., Director of the Board, chief medical officer, senior managing executive officer of Kyowa Kirin.
  • Under the terms of the agreement, Kyowa Kirin will initiate a scheme of arrangement to acquire all Orchard Therapeutics’ ADSs at a price of $16.00 per ADS in cash (or aggregated value of approximately $387.4 million, or approximately ¥57.3 billion) at closing, which represents a premium of 144% to Orchard Therapeutics’ volume-weighted average price per ADS over the previous 30 days ended October 4.
  • Following the completion of the acquisition, Orchard Therapeutics will become a wholly-owned subsidiary of Kyowa Kirin.

Xēnix Medical neoWave™ Interbody Systems Receive FDA Clearance for NANOACTIV™ Nanotechnology Surface

Retrieved on: 
Tuesday, October 10, 2023
Medical Devices, FDA, Health, Technology, Surgery, Nanotechnology, Incidence, Food, Stem cell, 3D, Biomedical engineering, MD, Subsidence, Pennsylvania State University, Arthrodesis, The King of Fighters Neowave, Biomedicine, Associate, SEM, Regulation of tobacco by the U.S. Food and Drug Administration, Patient, Medical device

The NANOACTIV implant surface demonstrates elements to be considered a nanotechnology as outlined in FDA nanotechnology guidance document.

Key Points: 
  • The NANOACTIV implant surface demonstrates elements to be considered a nanotechnology as outlined in FDA nanotechnology guidance document.
  • Ryan Phillips, President of Xēnix Medical, commented, “Receiving nanotechnology clearance for the neoWave interbody systems is an incredible milestone and achievement for Xēnix, elevating the neoWave implant systems into a distinct device category shared only by a few companies in the industry.
  • As we actively develop a complete line of neoWave interbody devices, the NANOACTIV surface will be a dominant enhancement of future implant systems.
  • The unique combination of a nanotechnology surface and completely latticed implant presents a significant breakthrough in treating patients that require interbody fusion.

Mount Sinai Launches Discovery and Innovation Center in Midtown West

Retrieved on: 
Friday, October 6, 2023
Human Genome Sciences, Personalized medicine, Engineering, Rensselaer Polytechnic Institute, Environment, Research, Bernard, Orthopedic surgery, Mount Sinai Health System, DNA, Proteomics, DVM, Stem cell, Health, Neuroscience, MTR, Icahn School of Medicine at Mount Sinai, Metabolomics, Biotechnology, Medicine, Genomics, Dermatology, The Center, Investment, Partnership, Innovation Center station, Doctor of Philosophy, New Center, Detroit, Eleventh Avenue, Microscopy, Icahn, Therapy, Discovery, Laboratory, FAAD, Immunology, Science, Sensation, Neuroinflammation, Patient, Pharmaceutical industry, Hospital, Mount Sinai West, Innovation, MD, Genetics

NEW YORK, Oct. 6, 2023 /PRNewswire-PRWeb/ -- New Center to Expand Research Capabilities and Bring Leading Researchers in Health Care, Innovation, and Basic Science Together at Mount Sinai West Campus.

Key Points: 
  • Today, the Mount Sinai Health System, New York City's largest academic medical system, announced the opening of its new Discovery and Innovation Center with a ceremonial ribbon cutting.
  • But it will also foster unprecedented collaboration among world-class researchers at Icahn Mount Sinai and their clinical counterparts at Mount Sinai West."
  • "Mount Sinai West, which is situated close to the new Discovery and Innovation Center, has one of the best clinical neuroscience centers in the world.
  • "The opportunity to work in close collaboration with the researchers at the Discovery and Innovation Center will open up new possibilities both here on the West Side and in the fields of science and medicine," said Evan L. Flatow, MD, President of Mount Sinai West and Mount Sinai Morningside, and the Bernard J. Lasker Professor of Orthopaedics at Icahn Mount Sinai.

Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration

Retrieved on: 
Monday, October 2, 2023
Survivor, Heart, California Institute for Regenerative Medicine, MI, Myocardial infarction, Heart failure, Stem cell, Connective tissue, Research, AAV, CFS, AHA, Fibrosis, Regenerative medicine, Ischemia, Animal, CM, SAN, CIRM, American Heart, CMS, Rat, Therapy, Death, Gene, Medical device, Pharmaceutical industry, Vaccine, Circulation

Using this approach in a model of chronic ischemic injury we successfully achieved – for the first time – dose-dependent and durable improvements in heart function through cardiac regeneration,” said Tim Hoey, Ph.D., Chief Scientific Officer of Tenaya.

Key Points: 
  • Using this approach in a model of chronic ischemic injury we successfully achieved – for the first time – dose-dependent and durable improvements in heart function through cardiac regeneration,” said Tim Hoey, Ph.D., Chief Scientific Officer of Tenaya.
  • Tenaya researchers engineered a novel AAV capable of targeting CFs with increased infectivity compared to parental AAV serotypes.
  • As detailed in the Circulation article, this novel AAV reprogramming construct, when injected into the hearts of acute mouse MI and chronic rat MI models, achieved significant and dose-dependent improvement in cardiac functions.
  • Tenaya is continuing its cardiac reprogramming research in preclinical studies of large animals using Tenaya’s proprietary injection catheter with support from grant funding from the California Institute for Regenerative Medicine (CIRM).

Edward Owusu Kwarteng, Ph.D., BSc, MSc, Honored With The 2023 ASH-CIBMTR-ASTCT Career Development Award

Retrieved on: 
Monday, October 2, 2023
University of Texas Southwestern Medical Center, National Marrow Donor Program, University, MCW, ASH, Senior, Virology, Medical college, Exposition, Transplant, Cell, Stem cell, Bachelor of Science, Health, University of Cape Coast, Glycolysis, Metabolism, MD, Patient, NMDP, Master of Science, Diversity, Medical College of Wisconsin, Inclusion, INRS, B cell, Society, Synthetic biology, Hematopoietic stem cell transplantation, Nursing, Hematology, Research

This award is exclusively for clinical and translational researchers who plan to practice hematopoietic stem cell transplantation and cellular therapy clinical patient care.

Key Points: 
  • This award is exclusively for clinical and translational researchers who plan to practice hematopoietic stem cell transplantation and cellular therapy clinical patient care.
  • The CIBMTR is a research collaboration between the National Marrow Donor Program® (NMDP)/Be The Match® and the Medical College of Wisconsin (MCW).
  • The award is part of a program to increase racial and ethnic diversity in the next generation of medical professionals.
  • Dr. Kwarteng receives registration for the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR.

Mogrify Extends Series A Financing to $46 Million USD

Retrieved on: 
Monday, October 2, 2023
Diabetes, Health, Pharmaceutical, Optical, Clinical Trials, Ear, Hearing loss, Stem cell, Eye, Pancreas, USP, Regenerative medicine, Limited, Sensorineural hearing loss, Patient, Abcam, Paratriathlon, Pharmaceutical industry

Mogrify Limited (Mogrify®), a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, announced today an additional $10 million USD closing of its Series A financing, bringing the total raised to $46 million USD in this round.

Key Points: 
  • Mogrify Limited (Mogrify®), a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, announced today an additional $10 million USD closing of its Series A financing, bringing the total raised to $46 million USD in this round.
  • The funding will support further advancement of Mogrify’s pipeline of in vivo reprogramming therapies through pre-clinical translation, continued platform optimization, and facilitation of new and existing biopharma collaborations.
  • Proceeds from the financing will be used to advance Mogrify’s pipeline of in vivo reprogramming therapies, delivering the milestones necessary to facilitate a Series B fundraise in 2024/25 and subsequent progression of a lead program into first-in-human studies.
  • Mogrify’s proprietary platform technologies enable systematic identification of the key transcriptomic and epigenetic cell switches required to control human cell fate.